Alerts will be sent to your verified email
Verify EmailDCAL
|
Dishman Carbogen Amc
|
Zenotech Labs.
|
Jeevan Scientific
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
US DMF Filings
|
18.0 . | n/a | n/a |
|
Total reactor capacity
|
1150.0 kL | n/a | n/a |
|
R&D as a % of Total Sales
|
1.64 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
0.08 % | 12.1 % | 11.56 % |
|
5yr average Equity Multiplier
|
1.61 | 1.13 | 1.54 |
|
5yr Average Asset Turnover Ratio
|
0.26 | 0.36 | 0.67 |
|
5yr Avg Net Profit Margin
|
-2.96 % | -13.89 % | 6.3 % |
|
Price to Book
|
0.46 | 2.94 | 2.2 |
|
P/E
|
31.5 | 0.0 | 137.26 |
|
5yr Avg Cash Conversion Cycle
|
24.66 Days | -1217.81 Days | -134.98 Days |
|
Inventory Days
|
110.18 Days | 145.01 Days | 12.33 Days |
|
Days Receivable
|
77.38 Days | 61.38 Days | 110.0 Days |
|
Days Payable
|
156.95 Days | 477.06 Days | 504.46 Days |
|
5yr Average Interest Coverage Ratio
|
0.4 | -4.03 | 4.93 |
|
5yr Avg ROCE
|
0.91 % | 9.71 % | 13.74 % |
|
5yr Avg Operating Profit Margin
|
13.93 % | 5.56 % | 18.71 % |
|
5 yr average Debt to Equity
|
0.3 | 0.04 | 0.24 |
|
5yr CAGR Net Profit
|
n/a | n/a | -60.01 % |
|
5yr Average Return on Assets
|
-0.73 % | 8.4 % | 5.42 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
59.32 % | 68.84 % | 30.25 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.0 | -8.19 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-1.26 % | 0.0 | 0.0 |
|
Dishman Carbogen Amc
|
Zenotech Labs.
|
Jeevan Scientific
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
Operating Profit Break-Up
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|